The Inhalation CDMO Market Size was valued at USD 7.9 Bn in 2023 and is predicted to reach USD 11.8 Bn by 2031 at a 5.2% CAGR during the forecast period for 2024-2031.
Inhalation CDMO refers to the organization that is responsible for the development and manufacturing of inhalation contracts. For the research and production of inhalation medicinal products, these specialized service providers offer solutions that cover the entire continuum. One of the main factors fueling the growth of the inhalation CDMO market is the increasing number of respiratory disorders globally. Air pollution, an aging population, and increased urbanization are contributing to the alarming increase in chronic obstructive pulmonary disease, cystic fibrosis, and asthma cases.
The inhalation CDMO industry is leading the way in technological innovation, improving inhalation medicines' safety, effectiveness, and patient experience by utilizing new ideas in aerosol science, device design, and manufacturing processes. Furthermore, the inhalation CDMO market has a lot of potential due to factors such the growing need for novel inhalation medicines, improvements in drug delivery technologies, and the trend of pharmaceutical companies outsourcing more and more to simplify production and development.
However, the market growth is hampered due to complex formulation procedures, high development and manufacturing expenses, and strict regulatory restrictions. Smaller businesses find it challenging to break into a market due to the high operational costs caused by the requirement for specialized equipment and experience. The COVID-19 pandemic has sped up the inhalation CDMO market because of higher demand for respiratory treatments, shorter lead times for drug development, and a greater focus on advanced drug delivery methods. This has led to more investment and new ideas in the inhalation CDMO market. Furthermore, rising collaborations between pharmaceutical firms and CDMO to address critical healthcare demands, faster drug approval processes, and heightened attention to respiratory health all contributed to the market's meteoric rise.
Competitive Landscape
Some of the Major Key Players in the Inhalation CDMO Market are
- Recipharm AB
- AptarGroup Inc.
- Hovione
- Vectura Group Ltd
- Nemera
- Kindeva
- H&T Presspart
- Sanner GmbH
- Stevanato Group
- Medspray
- ICONOVO AB
- Lonza
- Gerresheimer AG
- Catalent
- Thermo Fisher Scientific Inc.
- Lubrizol Life Science
- Enteris BioPharma
- Cambrex Corporation
- INKE
- Piramal Pharma Limited
- Lupin
- Others
Market Segmentation:
The global inhalation CDMO market is segmented based on service, product, company size and scale of operation. Based on service, the market is segmented into formulation development, device development and manufacturing, clinical manufacturing, scale-up and tech transfer, quality control and quality assurance, technology and innovation, regulatory assistance, and analytical services. By product, the market is segmented into API and inhalation platforms. The market is segmented by company size into large, medium, and small. By scale of operation, the market is segmented into preclinical, clinical, and commercial.
The Formulation Development Segment is Accounted as a Major Contributor to the Inhalation CDMO Market
The formulation development segment is expected to hold a major global market share in 2023 because new and improved inhalation treatments are in high demand. A lot of investment and effort has gone into developing effective drug delivery methods, assuring medication stability, and meeting demanding regulatory standards. To achieve these goals, advanced formulation processes are essential, which in turn drives their widespread use and substantial market share.
Inhalation Platform Segment to Witness Growth at a Rapid Rate
The inhalation platform segment in the inhalation CDMO market is growing because there is a growing need for focused and effective drug delivery systems for respiratory disorders. This market is experiencing rapid innovation due to technological advancements like dry powder inhalers and metered-dose inhalers. The demand for safe and effective inhalation treatments is another factor driving the expansion of inhalation platforms.
In the Region, the North American Inhalation CDMO Market Holds a Significant Revenue Share
The North American inhalation CDMO market is expected to register the highest market share in revenue in the near future. This is because there is a robust healthcare system, many people suffer from respiratory illnesses, a lot of money spent on research and development, and a powerful pharmaceutical sector. Major inhalation businesses are located in the region, which helps fuel the expansion of the market. In addition, Asia Pacific is projected to grow rapidly in the global inhalation CDMO market as a result of its burgeoning pharmaceutical industry, skyrocketing healthcare costs, increasing number of cases of respiratory disorders, and skyrocketing spending in R&D. Additionally, market expansion in the region is being propelled by a big patient population and supportive government efforts.
Recent Developments:
- In May 2024, ReciBioPharm, a business unit of Recipharm that develops new and advanced therapies, announced a partnership with GeneVentiv Therapeutics, a preclinical gene therapy company. The two will collaborate to develop an AAV-based universal gene therapy for hemophilia, which will be the first treatment for hemophilia patients with inhibitors.
- In June 2024, Aptar Digital Health, a frontrunner in the field of digital health solutions, connected devices, and disease management, announced a partnership with SHL Medical, a frontrunner in the field of advanced medication delivery systems (including autoinjectors, pen injectors, and specialized delivery systems), today. To further assist patients undergoing injectable treatment in managing their condition, the partnership will expand SHL Medical’s linked device technologies by including Aptar Digital Health’s SaMD platform.
Inhalation CDMO Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 7.95 Bn |
|
Revenue Forecast In 2031 |
USD 11.85 Bn |
|
Growth Rate CAGR |
CAGR of 5.2% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Service, By Application, By Company Size, By Scale of Operation |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Recipharm AB, AptarGroup Inc., Hovione, Vectura Group Ltd, Nemera, Kindeva, H&T Presspart, Sanner GmbH, Stevanato Group, Medspray, ICONOVO AB, Lonza, Gerresheimer AG, Catalent, Thermo Fisher Scientific Inc., Lubrizol Life Science, Enteris BioPharma, Cambrex Corporation, INKE, Piramal Pharma Limited, Lupin, and Others. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
